

List of References

- Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. *Clin Pharmacol Ther.* 2011 Dec;90(6):844-51.
- Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka, FT, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. *Ann Intern Med.* 2003 Aug 19;139(4):258-66.
- Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. *Clin Pharmacol Ther.* 2007 Nov;82(5):572-8.
- Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. *BMJ.* 2012 Feb 9;344:e536.
- Ashton CH. Adverse effects of cannabis and cannabinoids. *Br J Anaesth.* 1999 Oct;83(4):637-49.
- Bédard M, Dubois S, Weaver B. 2007. The impact of cannabis on driving. *Can J Public Health.* 2007 Jan-Feb;98(1):6-11.
- Beech RA, Sterrett DR, Babiuk J, Fung H. Cannabinoid Hyperemesis Syndrome: A Case Report and Literature Review. *J Oral Maxillofac Surg.* 2015 Apr 10. [Epub ahead of print]
- Bloom JW, Kaltenborn WT, Paoletti P, Camilli A, Lebowitz MD. Respiratory effects of non-tobacco cigarettes. *Br Med J (Clin Res Ed).* 1987 Dec 12;295(6612):1516-8.
- Brecht M, Higuera-Alhino D, Shade SB, Hebert S, McCune JM, Abrams DI. Short-term effect of cannabinoids on immune phenotype and function in HIV-1-infected patients. *J Clin Pharmacol.* 2002 Nov;42(11 Suppl):82S-80S.
- Cerda M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. *Drug Alcohol Depend.* 2012 Jan 1;120(1-3):22-7.
- Chao C, Jacobson LP, Tashkin D, Martínez-Maza O, Roth MD, Margolick JB, et al. Recreational drug use and T lymphocyte subpopulations in HIV-uninfected and HIV-infected men. *Drug Alcohol Depend.* 2008 Apr 1;94(1-3):165-71.
- Chemic Laboratories. Evaluation Of Volcano® Vaporizer For The Efficient Emission Of THC, CBD, CBN And The Significant Reduction And/Or Elimination Of Polynuclear-Aromatic (PNA) Analytes Resultant Of Pyrolysis. Canton, MA. 2003.

- Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. *PLoS One*. 2013 Oct 24;8(10):e76635.
- Earleywine M, Barnwell SS. Decreased respiratory symptoms in cannabis users who vaporize. *Harm Reduct J*. 2007 Apr 16;4:11.
- Engels FK, de Jong FA, Sparreboom A, Mathot RA, Loos WJ, Kitzen JJ, et al. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. *Oncologist*. 2007 Mar;12(3):291-300.
- Flockhart, DA. Drug interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine [Internet]. 2007. [cited 2015 Sep 9]. Available from: <http://medicine.iupui.edu/clinpharm/ddis/>
- Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marijuana. *Neurotoxicol Teratol*. 2003 Jul-Aug;25(4):427-36.
- Frost L, Mostofsky E, Rosenbloom JI, Mukamal KJ, Mittleman MA. Marijuana use and long-term mortality among survivors of acute myocardial infarction. *Am Heart J*. 2013 Feb;165(2):170-5.
- Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. *Addiction*. 2004 Jun;99(6):686-96.
- Galli JA, Sawaya RA, Friedenber FK. Cannabinoid hyperemesis syndrome. *Curr Drug Abuse Rev*. 2011 Dec;4(4):241-9.
- Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. *Epilepsia*. 2015 Aug;56(8):1246-51.
- Goldschmidt L, Richardson GA, Willford JA, Severtson SG, Day NL. School achievement in 14-year-old youths prenatally exposed to marijuana. *Neurotoxicol Teratol*. 2012 Jan-Feb;34(1):161-7.
- Grotenhermen F. Nonpsychological Adverse Effects. In: Pertwee R, editor. *Handbook of Cannabis*. Oxford: Oxford University Press; 2015. p. 674-91.
- Habboushe J, Sedor J. Cannabinoid hyperemesis acute renal failure: a common sequel of cannabinoid hyperemesis syndrome. *Am J Emerg Med*. 2014 Jun;32(6):690.

- Hall W, Solowij N. Adverse effects of cannabis. *Lancet*. 1998 Nov 14;352(9140):1611-6.
- Hanus L. Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. *Med Res Rev*. 2009 Mar;29(2):213-71.
- Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, et al. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. *Clin Chem*. 2015 Jun;61(6):850-69.
- Iacopetti CL, Packer CD. Cannabinoid hyperemesis syndrome: a case report and review of pathophysiology. *Clin Med Res*. 2014 Sep;12(1-2):65-7.
- Jouanjus E, Lapeyre-Mestre M, Micallef J, French Association of the Region Abuse and Dependence Monitoring Centres (CEIP-A) Working Group on Cannabis Complications. Cannabis use: signal of increasing risk of serious cardiovascular disorders. *J Am Heart Assoc*. 2014 Apr 23;3(2)e000638.
- Kemper JA, Honig EG, Martin GS. The effects of marijuana exposure on expiratory airflow. A study of adults who participated in the U.S. National Health and Nutrition Examination Study. *Ann Am Thorac Soc*. 2015 Feb;12(2):135-41.
- Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. *Psychol Med*. 2014 Mar;44(4):797-810.
- Luther V, Yap L. A hot bath to calm what ails you: the Cannabis Hyperemesis Syndrome. *Acute Med*. 2012;11(1):23-4.
- Macleod J, Robertson R, Copeland L, McKenzie J, Elton R, Reid P. Cannabis, tobacco smoking, and lung function: a cross-sectional observational study in a general practice population. *Br J Gen Pract*. 2015 Feb;65(631):e89-95.
- Martyny JW, Serrano KA, Schaeffer JW, Van Dyke MV. Potential exposures associated with indoor marijuana growing operations. *J Occup Environ Hyg*. 2013;10(11):622-39.
- McLaren J, Swift W, Dillon P, Allsop S. Cannabis potency and contamination a review of the literature. *Addiction*. 2008 Jul;103(7):1100-9.
- McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, Kyprianou K. Cannabis and schizophrenia. *Cochrane Database Syst Rev*. 2014 Oct 14;10:CD004837.
- McPartland JM, Pruitt PL. Medical marijuana and its use by the immunocompromised. *Altern Ther Health Med*. 1997 May;3(3): 39-45.

- Meier MH, Caspi A, Ambler A, Harrington HL, Houts R, Keefe RSE, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci USA*. 2012 Oct 2;109(40):E2657-E2664.
- Metz TD, Stickrath EH. Marijuana use in pregnancy and lactation: a review of the evidence. *Am J Obstet Gynecol*. 2015 May 15. [Epub ahead of print]
- Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. *Circulation*. 2001 Jun 12;103(23):2805-9.
- Montgomery C, Seddon AL, Fisk JE, Murphy PN, Jansari A. Cannabis-related deficits in real-world memory. *Hum Psychopharmacol*. 2012 Mar;27(2):217-25.
- Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet*. 2007 Jul 28;370(9584):319-28.
- Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. *Br J Psychiatry*. 2008 Apr;192(4):306-7.
- Morrison PD, Bhattacharyya S, Murray RM. Recreational cannabis: the risk of schizophrenia. In: Pertwee R, editor. *Handbook of Cannabis*. Oxford: Oxford University Press; 2015. p. 661-73.
- Notcutt W, Clarke EL. Cannabinoids in clinical practice: a UK perspective. In: Pertwee R, editor. *Handbook of Cannabis*. Oxford: Oxford University Press; 2015. p. 415-432.
- Ocampo TL, Rans TS. Cannabis sativa: the unconventional “weed” allergen. *Ann Allergy Asthma Immunol*. 2015 Mar;114(3):187-92.
- Pletcher MJ, Vittinghoff E, Kalhan R, Richman J, Safford M, Sidney S, et al. Association between marijuana exposure and pulmonary function over 20 years. *JAMA*. 2012 Jan 11;307(2):173-81.
- Power BD, Dragovic M, Badcock JC, Morgan VA, Castle D, Jablensky A, et al. No additive effect of cannabis on cognition in schizophrenia. *Schizophr Res*, 2015 Jul 30. [Epub ahead of print]
- Price JS, McQueeney T, Shollenbarger S, Browning EL, Wieser J, Lisdahl KM. Effects of marijuana use on prefrontal and parietal volumes and cognition in emerging adults. *Psychopharmacology (Berl)*. 2015 Aug;232(16):2939-50.
- Reprotox.org [Internet]. c1994-2015 [cited 2015 Sep 9]. Available from: <https://reprotox.org/>

- Roebke PV, Vadhan NP, Brooks DJ, Levin FR. Verbal learning in marijuana users seeking treatment: a comparison between depressed and non-depressed samples. *Am J Drug Alcohol Abuse*. 2014 Jul;40(4):274-9.
- Rubino T, Zamberletti E, Parolaro D. Adolescent exposure to cannabis as a risk factor for psychiatric disorders. *J Psychopharmacol*. 2012 Jan;26(1):177-88.
- Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. *Schizophr Res*. 2011 Aug;130(1-3):216-21.
- Sparacino CM, Hyldborg PA, Hughes TJ. Chemical and biological analysis of marijuana smoke condensate. *NIDA Res Monogr*. 1990;99:121-40.
- Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. *Drug Metab Rev*. 2014 Feb;46(1):86-95.
- Tan WC, Lo C, Jong A, Xing L, Fitzgerald MJ, Vollmer WM, et al. Marijuana and chronic obstructive lung disease: a population-based study. *CMAJ*. 2009 Apr 14;180(8):814-20.
- Tashkin DP. Effects of marijuana smoking on the lung. *Ann Am Thorac Soc*. 2013 Jun;10(3):239-47.
- Tashkin DP. Increasing cannabis use: what we still need to know about its effects on the lung. *Respirology*. 2014 Jul;19(5):619-20.
- Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. *Am J Cardiol*. 2014 Jan 1;113(1):187-90.
- Thundermaker. Active/Lethal Dose Ratio and Dependent Potential of Psychoactive Drugs, Data Source: Gable R. S. (2006) [image]. Wikipedia; 2010.
- Turner CE, ElSohly MA, Boeren EG. Constituents of *Cannabis sativa* L. XVII. A review of the natural constituents. *J Nat Prod*. 1980 Mar-Apr;43(2):169-234.
- Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. *Life Sci*. 2007 Mar 20;80(15):1415-9.
- Woods JA, Wright NJ, Gee J, Scobey MW. Cannabinoid Hyperemesis Syndrome: An Emerging Drug-Induced Disease. *Am J Ther*. 2014 Jan 9. [Epub ahead of print]

- Wu LT, Woody GE, Yang C, Pan JJ, Reeve BB, Blazer DG. A dimensional approach to understanding severity estimates and risk correlates of marijuana abuse and dependence in adults. *Int J Methods Psychiatr Res.* 2012 Jun;21(2):117-33.
- Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. *Drug Metab Pharmacokinet.* 2012;27(3):294-300.
- Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, et al. Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. *Int J Cancer.* 2015 Feb 15;136(4):894-903.